Madurai News

Intrahepatic Cholangiocarcinoma Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

 Breaking News
  • No posts were found

Intrahepatic Cholangiocarcinoma Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

October 03
19:31 2022
Intrahepatic Cholangiocarcinoma Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Intrahepatic Cholangiocarcinoma pipeline constitutes 20+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Intrahepatic Cholangiocarcinoma Overview

Cancer that occurs in the parts of the bile ducts that are within the liver is called intrahepatic cholangio carcinoma (ICC), also known as intrahepatic bile duct cancer. ICC is a rare disease and makes up about 10% of all cholangio carcinoma.

 

Intrahepatic Cholangiocarcinoma Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Intrahepatic Cholangiocarcinoma Market. 

 

The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Intrahepatic Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. Intrahepatic Cholangiocarcinoma Key players such as – Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd, Basilea Pharmaceuticals, and others, are developing therapies for the Intrahepatic Cholangiocarcinoma treatment 
  • Intrahepatic Cholangiocarcinoma Emerging therapies such as – XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others are expected to have a significant impact on the Intrahepatic Cholangiocarcinoma market in the coming years.   
  • In December 2012, Basilea Pharmaceuticals initiated a Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangio carcinomaWith FGFR2 Gene Fusion
  • In November 2017, Basilea Pharmaceuticals initiated a Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications 

 

Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment

  • Intrahepatic Cholangiocarcinoma Assessment by Product Type
  • Intrahepatic Cholangiocarcinoma By Stage and Product Type
  • Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
  • Intrahepatic Cholangiocarcinoma By Stage and Route of Administration
  • Intrahepatic Cholangiocarcinoma Assessment by Molecule Type
  • Intrahepatic Cholangiocarcinoma by Stage and Molecule Type 

 

DelveInsight’s Intrahepatic Cholangiocarcinoma Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Intrahepatic Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:

  • XmAb®22841: Xencor, Inc.
  • RLY-4008: Relay Therapeutics
  • KIN-3248: Kinnate Biopharma
  • FT-2102: Forma Therapeutics, Inc.
  • SD 101: TriSalus Life Sciences
  • Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
  • VG161: Virogin Biotech Ltd
  • Derazantinib: Basilea Pharmaceuticals 

 

Intrahepatic Cholangiocarcinoma Pipeline Analysis:

 

The Intrahepatic Cholangiocarcinoma pipeline report provides insights into 

  •  The report provides detailed insights about companies that are developing therapies for the Intrahepatic Cholangiocarcinoma treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma Treatment.
  • Intrahepatic Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Intrahepatic Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Intrahepatic Cholangiocarcinoma product details are provided in the report. Download the Intrahepatic Cholangiocarcinoma pipeline report to learn more about the emerging Intrahepatic Cholangiocarcinoma therapies

 

Intrahepatic Cholangiocarcinoma Pipeline Market Drivers

  • Rising incidence of Cholangiocarcinoma. Intrahepatic Cholangiocarcinoma makes up 8–10% of all cholangio carcinoma.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Intrahepatic Cholangiocarcinoma

 

Intrahepatic Cholangiocarcinoma Pipeline Market Barriers

  • Poor prognosis and diagnosis of the disease
  • Difficulty in developing novel therapies. Drugs may lose effectiveness after several months as the tumor may become resistant to the medication

 

Get a Free Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma Pipeline Assessment

 

Scope of Intrahepatic Cholangiocarcinoma Pipeline Drug Insight    

  • Coverage: Global
  • Key Intrahepatic Cholangiocarcinoma Companies: Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd, Basilea Pharmaceuticals, and others
  • Key Intrahepatic Cholangiocarcinoma Therapies: XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others
  • Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
  • Intrahepatic Cholangiocarcinoma Market Dynamics:  Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers 

 

Request for Sample PDF Report for Intrahepatic Cholangiocarcinoma Pipeline Assessment and clinical trials 

 

Table of Contents

1

Intrahepatic Cholangiocarcinoma Report Introduction

2

Intrahepatic Cholangiocarcinoma Executive Summary

3

Intrahepatic Cholangiocarcinoma Overview

4

Intrahepatic Cholangiocarcinoma- Analytical Perspective In-depth Commercial Assessment

5

Intrahepatic Cholangiocarcinoma Pipeline Therapeutics

6

Intrahepatic Cholangiocarcinoma Late Stage Products (Phase II/III)

7

Intrahepatic Cholangiocarcinoma Mid Stage Products (Phase II)

8

Intrahepatic Cholangiocarcinoma Early Stage Products (Phase I)

9

Intrahepatic Cholangiocarcinoma Preclinical Stage Products

10

Intrahepatic Cholangiocarcinoma Therapeutics Assessment

11

Intrahepatic Cholangiocarcinoma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Intrahepatic Cholangiocarcinoma Key Companies

14

Intrahepatic Cholangiocarcinoma Key Products

15

Intrahepatic Cholangiocarcinoma Unmet Needs

16 

Intrahepatic Cholangiocarcinoma Market Drivers and Barriers

17

Intrahepatic Cholangiocarcinoma Future Perspectives and Conclusion

18

Intrahepatic Cholangiocarcinoma Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/